Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. GlaxoSmithKline plc
  6. News
  7. Summary
    GSK   GB0009252882

GLAXOSMITHKLINE PLC

(GSK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

GlaxoSmithKline : EMA Starts Rolling Review Of GSK/Vir COVID-19 Vaccine

05/07/2021 | 06:51am EDT


© MT Newswires 2021
All news about GLAXOSMITHKLINE PLC
07/29GLAXOSMITHKLINE : GSK Wins Fourth Approval for Chronic Rhinosinusitis Drug Nucal..
MT
07/29GlaxoSmithKline plc Announces FDA Approval for Nucala (Mepolizumab) for Use i..
CI
07/29GLAXOSMITHKLINE : Gsk Announces FDA Approval For Nucala For Use In Adults With C..
RE
07/29Exclusive - AstraZeneca exploring options for COVID-19 vaccine business - exe..
RE
07/29GLAXOSMITHKLINE : Credit Suisse keeps a Sell rating
MD
07/29GLAXOSMITHKLINE : Barclays Lifts GlaxoSmithKline PT, Maintains Underweight Ratin..
MT
07/29GLAXOSMITHKLINE : Barclays reiterates its Sell rating
MD
07/29GLAXOSMITHKLINE : UBS reiterates its Neutral rating
MD
07/29GLAXOSMITHKLINE : Deutsche Bank remains Neutral
MD
07/29GLAXOSMITHKLINE : Q2 2021 results transcript PDF - 168.2KB
PU
More news
Financials
Sales 2021 33 289 M 46 264 M 46 264 M
Net income 2021 3 621 M 5 032 M 5 032 M
Net Debt 2021 20 751 M 28 839 M 28 839 M
P/E ratio 2021 19,4x
Yield 2021 5,64%
Capitalization 70 948 M 98 661 M 98 602 M
EV / Sales 2021 2,75x
EV / Sales 2022 2,61x
Nbr of Employees 94 066
Free-Float 92,2%
Chart GLAXOSMITHKLINE PLC
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE PLC
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Last Close Price 1 417,80 GBX
Average target price 1 534,54 GBX
Spread / Average Target 8,23%
EPS Revisions
Managers and Directors
Emma N. Walmsley Chief Executive Officer & Executive Director
Iain James Mackay Chief Financial Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Karenann K. Terrell Chief Digital & Technology Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
GLAXOSMITHKLINE PLC5.65%98 661
JOHNSON & JOHNSON9.42%453 418
ROCHE HOLDING AG12.49%335 069
PFIZER, INC.16.30%239 525
NOVARTIS AG-0.16%224 495
ELI LILLY AND COMPANY44.22%223 011